Bayer rallies on restructuring and medical advances

After years of disappointing performance, Bayer's stock has surged 88% since early 2025, driven by restructuring announcements and strategic shifts in its pharmaceutical business. Concurrently, Bayer has launched a Phase IIa clinical trial for a treatment targeting the rare genetic Alport syndrome, strengthening its R&D pipeline. These combined factors have boosted investor confidence in the German group's turnaround potential, despite medium-term returns remaining negative.